Genome Biologics is a Biotherapeutics company headquartered in Germany with a strong background and proven track record in in silico drug screening, in vivo preclinical drug testing and state-of-the-art transgenic technologies.



Established by industrial and academic experts and supported by leading academic institutions, CROs and the pharmaceutical industry, Genome Biologics combines the power of Artificial Intelligence based machine learning with big data, genomics and molecular science to rapidly identify drug-disease matches and generate complex in-vivo disease models.